Cargando…

The R Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis

The novel nitroimidazopyran agent (S)-PA-824 has potent antibacterial activity against Mycobacterium tuberculosis in vitro and in vivo and is currently in phase II clinical trials for tuberculosis (TB). In contrast to M. tuberculosis, where (R)-PA-824 is inactive, we report here that both enantiomer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patterson, Stephen, Wyllie, Susan, Stojanovski, Laste, Perry, Meghan R., Simeons, Frederick R. C., Norval, Suzanne, Osuna-Cabello, Maria, De Rycker, Manu, Read, Kevin D., Fairlamb, Alan H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2013
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811480/ https://www.ncbi.nlm.nih.gov/pubmed/23856774 http://dx.doi.org/10.1128/AAC.00722-13

Ejemplares similares

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis
por: Patterson, Stephen, et al.
Publicado: (2016)

Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis
por: Thomas, Michael, et al.
Publicado: (2021)

Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis
por: Thomas, Michael G., et al.
Publicado: (2020)

Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis
por: Wyllie, Susan, et al.
Publicado: (2018)

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition
por: Wyllie, Susan, et al.
Publicado: (2019)

Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani
por: Torrie, Leah S., et al.
Publicado: (2017)

Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei
por: Cleghorn, Laura A. T., et al.
Publicado: (2015)

Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity
por: Thomas, Michael G., et al.
Publicado: (2020)

Visceral Leishmaniasis and Arsenic: An Ancient Poison Contributing to Antimonial Treatment Failure in the Indian Subcontinent?
por: Perry, Meghan R., et al.
Publicado: (2011)

Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis
por: Thomas, Michael G., et al.
Publicado: (2018)

Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)
por: Baptista, Rafael, et al.
Publicado: (2018)

Whole-Cell Screen of Fragment Library Identifies Gut Microbiota Metabolite Indole Propionic Acid as Antitubercular
por: Negatu, Dereje A., et al.
Publicado: (2018)

Development of a 2,4-Diaminothiazole Series for the Treatment of Human African Trypanosomiasis Highlights the Importance of Static–Cidal Screening of Analogues
por: Cleghorn, Laura A. T., et al.
Publicado: (2023)

Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis
por: Jones, Deuan C., et al.
Publicado: (2010)

Structure of Ddn, the Deazaflavin-Dependent Nitroreductase from Mycobacterium tuberculosis Involved in Bioreductive Activation of PA-824
por: Cellitti, Susan E., et al.
Publicado: (2012)

Structure of Ddn, the Deazaflavin-Dependent Nitroreductase from Mycobacterium tuberculosis Involved in Bioreductive Activation of PA-824
por: Cellitti, Susan E., et al.
Publicado: (2013)

Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library
por: Woodland, Andrew, et al.
Publicado: (2015)

Visceral leishmaniasis
por: Sundar, Shyam
Publicado: (2015)

S-Enantiomer of the Antitubercular Compound S006-830 Complements Activity of Frontline TB Drugs and Targets Biogenesis of Mycobacterium tuberculosis Cell Envelope
por: Singh, Padam, et al.
Publicado: (2017)

Arsenic Exposure and Outcomes of Antimonial Treatment in Visceral Leishmaniasis Patients in Bihar, India: A Retrospective Cohort Study
por: Perry, Meghan R., et al.
Publicado: (2015)

Cordyceps sinensis promotes immune regulation and enhances bacteriostatic activity of PA-824 via IL-10 in Mycobacterium tuberculosis disease
por: Li, D.G., et al.
Publicado: (2017)

Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani
por: Corpas-Lopez, Victoriano, et al.
Publicado: (2018)

Correction to “S-Enantiomer of the Antitubercular Compound S006-830 Complements Activity of Frontline TB Drugs and Targets Biogenesis of Mycobacterium tuberculosis Cell Envelope”
por: Singh, Padam, et al.
Publicado: (2017)

Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2017)

Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy
por: Baragaña, Beatriz, et al.
Publicado: (2016)

Comparison of in vitro Susceptibility of Mycobacteria Against PA-824 to Identify Key Residues of Ddn, the Deazoflavin-Dependent Nitroreductase from Mycobacterium tuberculosis
por: Zhang, Fuzhen, et al.
Publicado: (2020)

Congenital Visceral Leishmaniasis
por: Boehme, Catharina C., et al.
Publicado: (2006)

Immunity to Visceral Leishmaniasis
por: Ali, Nahid, et al.
Publicado: (2012)

Treatment of Visceral Leishmaniasis
por: Moore, E M, et al.
Publicado: (2010)

Immunobiology of visceral leishmaniasis
por: Kumar, Rajiv, et al.
Publicado: (2012)

Epidemiology of visceral leishmaniasis
por: Ready, Paul D
Publicado: (2014)

AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2
por: Fahy, B N, et al.
Publicado: (2003)

DECREASED EFFECT OF GLUCANTIME IN CUTANEOUS LEISHMANIASIS COMPLICATED WITH SECONDARY BACTERIAL INFECTION
por: Sadeghian, G, et al.
Publicado: (2011)

Anti-trypanosomatid drug discovery: progress and challenges
por: De Rycker, Manu, et al.
Publicado: (2022)

Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered In Vivo Screening Paradigm for Development of Drugs To Treat Cutaneous Leishmaniasis
por: Caridha, Diana, et al.
Publicado: (2017)

Comparison of Intralesional Two Percent Zinc Sulfate and Glucantime Injection in Treatment of Acute Cutaneous Leishmaniasis
por: Maleki, Masoud, et al.
Publicado: (2012)

THE COMPARISON BETWEEN TRICHLOROACETIC ACID 50% AND CO(2) LASER IN THE TREATMENT OF CUTANEOUS LEISHMANIASIS SCAR
por: Nilforoushzadeh, Mohammad Ali, et al.
Publicado: (2011)

Relationship of Serum Antileishmanial Antibody With Development of Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis and Visceral Leishmaniasis Relapse
por: Mondal, Dinesh, et al.
Publicado: (2019)

Lead Optimization of a Pyrazole Sulfonamide Series of Trypanosoma bruceiN-Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis
por: Brand, Stephen, et al.
Publicado: (2014)

Visceral Leishmaniasis Treatment, Italy
por: Gradoni, Luigi, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_83bqs9e1msq5iq13gvffr5kd0q